07th week of 2019 patent applcation highlights part 8 |
Patent application number | Title | Published |
20190046398 | PERFUSION DOSAGE FORM - The present invention relates to a method for enabling hospitals or clinics to administer a dose of a drug to patients in need thereof while avoiding steps of manipulation, dilution, reconstitution, dispensing, sterilization, transfer, handling or compounding before intravenous administration. | 2019-02-14 |
20190046399 | MODULAR DOSING ASSEMBLY OF MEDICAL SUBSTANCES - Systems, devices and method to establish fluid communication between vessels. A vessel having at least two entry ports and at least one exit port, and at least one container containing a dosing regimen, the at least one container configured to be received by one of the at least two entry ports of the vessel, whereby upon connection of the at least one container to the one of the at least two entry ports of the vessel, the dosing regimen in the at least one container is transferred into the vessel. Modular dosing system for adding at least one amount of a medicament to a preparation in a modular construction. System for displaying a dosing regimen or single amount of a medicament, so that the administrator of the amount is able to precisely ascertain the amount administered to a patient. | 2019-02-14 |
20190046400 | MODULAR DOSING ASSEMBLY OF MEDICAL SUBSTANCES - Systems, devices and method to establish fluid communication between vessels. A vessel having at least two entry ports and at least one exit port, and at least one container containing a dosing regimen, the at least one container configured to be received by one of the at least two entry ports of the vessel, whereby upon connection of the at least one container to the one of the at least two entry ports of the vessel, the dosing regimen in the at least one container is transferred into the vessel. Modular dosing system for adding at least one amount of a medicament to a preparation in a modular construction. System for displaying a dosing regimen or single amount of a medicament, so that the administrator of the amount is able to precisely ascertain the amount administered to a patient. | 2019-02-14 |
20190046401 | BAG ASSEMBLY AND BAG SYSTEM FOR USE WITH A FLUID - A bag assembly includes a first panel secured to a second panel by a seam so that a cavity is formed between the first panel and the second panel, the seam encircling the cavity. A first seal couples together the first panel and the second panel at a location spaced apart from the seam so that the cavity encircles the first seal. In one embodiment, the first seal can be circular. A first port communicates with the cavity. | 2019-02-14 |
20190046402 | RECONSTITUTION DEVICE, SYSTEM, AND METHOD TO ADMINISTER A DRUG IN A MODERATE BOLUS - A reconstitution device includes: a piercing member having a first end and a second end, the first end of the piercing member configured to engage an administration port; a delivery member having a first end and a second end, the first end of the delivery member configured to engage a delivery site; a collar configured to engage a vial; and a cap extending from the collar and holding the piercing member and the delivery member such that the second end of the piercing member and the second end of the delivery member are disposed within the cylindrical collar. | 2019-02-14 |
20190046403 | MODULAR DOSING ASSEMBLY OF MEDICAL SUBSTANCES - Systems, devices and method to establish fluid communication between vessels. A vessel having at least two entry ports and at least one exit port, and at least one container containing a dosing regimen, the at least one container configured to be received by one of the at least two entry ports of the vessel, whereby upon connection of the at least one container to the one of the at least two entry ports of the vessel, the dosing regimen in the at least one container is transferred into the vessel. Modular dosing system for adding at least one amount of a medicament to a preparation in a modular construction. System for displaying a dosing regimen or single amount of a medicament, so that the administrator of the amount is able to precisely ascertain the amount administered to a patient. | 2019-02-14 |
20190046404 | MODULAR DOSING ASSEMBLY OF MEDICAL SUBSTANCES - Systems, devices and method to establish fluid communication between vessels. A vessel having at least two entry ports and at least one exit port, and at least one container containing a dosing regimen, the at least one container configured to be received by one of the at least two entry ports of the vessel, whereby upon connection of the at least one container to the one of the at least two entry ports of the vessel, the dosing regimen in the at least one container is transferred into the vessel. Modular dosing system for adding at least one amount of a medicament to a preparation in a modular construction. System for displaying a dosing regimen or single amount of a medicament, so that the administrator of the amount is able to precisely ascertain the amount administered to a patient. | 2019-02-14 |
20190046405 | Method for Fluid Delivery - A fill adapter for filling a reservoir and a related method are disclosed herein. The fill adapter includes a button assembly actuator and a pump chamber plunger actuator hingably attached to the button assembly actuator, wherein the actuation of the button assembly actuator actuates the pump chamber plunger actuator and wherein the pump chamber plunger actuator actuates a pump chamber membrane before the at least one button assembly is actuated. | 2019-02-14 |
20190046406 | SEALER-LESS PLASMA BOTTLE AND TOP FOR SAME - A top for a plasma storage container includes a top body that defines the structure of the top and seals an opening of the plasma storage container. The top also includes a first opening and a vent opening extending through the top body. A valve mechanism is located at least partially within the top body and includes an aperture therethrough. The aperture opens upon connection of a blunt cannula to provide access to the interior of the plasma storage container. The top also includes a vent filter. The vent filter allows air to vent through the vent opening during plasma collection. | 2019-02-14 |
20190046407 | SPIKE PORT FOR MEDICAL SOLUTION BAG ASSEMBLY AND RELATED METHODS - A molded spike port including a first portion defining a first chamber, a plug disposed in the first chamber and configured to form a seal with the first portion, a second portion defining a second chamber, the second portion including a sealing ring configured to seal the spike port to a spike, a tip configured to be inserted into a fluid bag, the tip comprising a membrane, and a wall between the first portion and the second portion, wherein the wall is configured to break when the first portion is twisted relative to the second portion. | 2019-02-14 |
20190046408 | MODULAR DOSING ASSEMBLY OF MEDICAL SUBSTANCES - Systems, devices and method to establish fluid communication between vessels. A vessel having at least two entry ports and at least one exit port, and at least one container containing a dosing regimen, the at least one container configured to be received by one of the at least two entry ports of the vessel, whereby upon connection of the at least one container to the one of the at least two entry ports of the vessel, the dosing regimen in the at least one container is transferred into the vessel. Modular dosing system for adding at least one amount of a medicament to a preparation in a modular construction. System for displaying a dosing regimen or single amount of a medicament, so that the administrator of the amount is able to precisely ascertain the amount administered to a patient. | 2019-02-14 |
20190046409 | MODULAR DOSING ASSEMBLY OF MEDICAL SUBSTANCES - Systems, devices and method to establish fluid communication between vessels. A vessel having at least two entry ports and at least one exit port, and at least one container containing a dosing regimen, the at least one container configured to be received by one of the at least two entry ports of the vessel, whereby upon connection of the at least one container to the one of the at least two entry ports of the vessel, the dosing regimen in the at least one container is transferred into the vessel. Modular dosing system for adding at least one amount of a medicament to a preparation in a modular construction. System for displaying a dosing regimen or single amount of a medicament, so that the administrator of the amount is able to precisely ascertain the amount administered to a patient. | 2019-02-14 |
20190046410 | Syringe Adaptor and Complementary Fluid-Port Adaptor - A syringe adaptor includes a body, shaped to define a body lumen, a syringe fitting at a proximal end of the body, configured to connect to a distal end of a syringe, a needle extending distally from the syringe fitting into the body lumen, a septum housing, and an elastomeric septum mounted inside the septum housing. The septum includes a proximal face, shaped to define an aperture having an aperture diameter, and a distal face. The septum is shaped to define a cavity, joined to the aperture, having a cavity diameter that is larger than the aperture diameter. The septum housing is configured to slide proximally within the body lumen such that a distal end of the needle contained in the cavity passes through the distal face of the septum. Other embodiments are also described. | 2019-02-14 |
20190046411 | SUBLINGUAL AND BUCCAL FILM COMPOSITIONS - The present invention relates to products and methods for treatment of various symptoms in a patient, including treatment of pain suffered by a patient. The invention more particularly relates to self-supporting dosage forms which provide an active agent while providing sufficient buccal adhesion of the dosage form. Further, the present invention provides a dosage form which is useful in reducing the likelihood of diversion abuse of the active agent. | 2019-02-14 |
20190046412 | TABLET AND CAPSULE DISPENSING ASSEMBLY - A tablet and capsule dispensing assembly, comprising a case including an inner circumferential surface having a first plurality of teeth a tablet disc having a plurality of tablets disposed circumferentially thereon, the tablet disc arranged to rotate within the case, and a lock arranged to engage with the first plurality of teeth to prevent rotation of the tablet disc in a first rotational direction during a first predetermined time interval. | 2019-02-14 |
20190046413 | TEATS FOR FEEDING BOTTLES - A feeding teat for use with a bottle that contains a fluid includes a nipple defining an orifice at a terminal end and an interior profile shaped by multiple intersecting reverse curves that generally decreases an interior diameter of the nipple toward the orifice for directing a flow of the fluid into the orifice, a flange configured to be releasably coupled to the bottle such that the fluid can flow from the bottle into the feeding teat, an intermediate portion integrally connecting the nipple to the flange, and a pressure relief valve extending laterally from the intermediate portion and configured to admit air into an interior region formed by the feeding teat and the bottle. | 2019-02-14 |
20190046414 | PERSONALIZED PACIFIER AND BOTTLE NIPPLE - Disclosed are artificial nipples and methods of producing artificial nipples. Disclosed are methods of producing an artificial nipple comprising imaging a nipple region of a breast, wherein at least a portion of the breast comprising the nipple region is distorted due to at least a partial vacuum created through motions of lips and a tongue, wherein the imaging provides imaging data of the nipple region; and generating, based on the imaging data, an artificial nipple. | 2019-02-14 |
20190046415 | BABY BOTTLE WITH INTEGRATED PACIFIER APPARATUS AND METHOD OF USE - Embodiments described herein include a baby bottle with integrated pacifier apparatus and method of use including a substantially elongated baby bottle and nipple mounted assembly which includes a pressure valve mechanism configured to regulate the flow of liquid through the nipple and prevent excess air from being ingested. | 2019-02-14 |
20190046416 | SELF-EXPANDABLE TUBE AND METHOD OF USE - The invention relates to a self-expandable tube having a catheter body with a double lumen in which one lumen allows for suctioning or decompression and another lumen for a feeding tube. A self-expandable portion collects secretions above the expandable portion or in the anatomical lumen and a suction source coupled to the self-expandable tube removes the secretions as is disclosed herein. | 2019-02-14 |
20190046417 | FIBER-OPTIC REALSHAPE SENSING FEEDING TUBE - A FORS feeding tube system employing a feeding tube ( | 2019-02-14 |
20190046418 | DENTAL CEMENT COMPOSITION - The present invention relates to dental cement composition that is more biocompatible and stimulates quicker healing of the damaged dental tissues. Specifically, the invention relates to dental cement composition comprising a combination of dental repair compounds consisting of nanoparticles of Tri-calcium Silicate (Ca3SiO5), Di-calcium Silicate (Ca2SiO4), Calcium Titanate (CaTiO3) and Hydroxyapatite (Ca10(PO4)6(OH)2). | 2019-02-14 |
20190046419 | KIT OF PARTS FOR PRODUCING A PASTE TYPE GLASS IONOMER CEMENT, PROCESS OF PRODUCTION AND USE THEREOF - The invention relates to a kit of parts for preparing a glass ionomer composition for dental use, the kit comprising a Paste A and a Paste B, Paste A comprising water, acid-reactive inorganic filler A, phyllo silicate(s), Paste B comprising water, poly-acid, non acid-reactive filler B, optionally chelating agent. The invention also relates to a hardenable composition obtainable by combining the pastes of the kit or parts and to the use of such a composition as or for preparing a dental cement, dental filling mater ial, dental core build up material or dental root channel filling material. | 2019-02-14 |
20190046420 | DENTAL CEMENT - A dental cement includes: a first component containing a glass powder; a second component containing a polycarboxylic acid-based polymer, an organic polybasic acid, and water. The glass powder contains zinc and silicon. A solubility of a salt of a conjugate base of the organic polybasic acid and zinc ions in water at 20° C. is greater than or equal to 1 g/100 mL. | 2019-02-14 |
20190046421 | SPRAYABLE SUNSCREEN COSMETIC - A sprayable sunscreen cosmetic contains substantially no ultraviolet ray scattering agents which cause whiteness, and which is transparent immediately after being applied/sprayed, and that has excellent ultraviolet ray protection effect and a good sensation in use. The ultraviolet ray protection effect is not reduced, and the effects improve when in contact with water. A water-in-oil emulsified sunscreen cosmetic comprises: (A) 6 to 40 mass % of an ultraviolet ray absorbing agent; (B) an organically modified clay mineral; (C) an oil phase thickener other than the aforementioned (B); (D) a silicone-based surfactant having an HLB of less than 8; (E) a spherical resin powder; and (F) a volatile silicone oil; wherein a ratio defined as [total amount of ingredient (B) and ingredient (C)]/[total amount of (G) non-volatile liquid oils other than silicone oils] is at least 0.04 and less than 0.68. | 2019-02-14 |
20190046422 | ORGANIC HYDROPEROXIDE REDUCTION IN PERFUMERY RAW MATERIALS - The aspects presented herein provide methods and compositions for the reduction of the peroxide value of perfume ingredients, formulated perfumes, formulated body care products, formulated skin care products, formulated homecare products, essential oils, food raw materials, formulated food products, and natural extracts. | 2019-02-14 |
20190046423 | HAIR TREATMENT COMPOSITIONS AND METHODS - The present invention is directed to the hair care treatment compositions, including pre- and post-treatment compositions, containing select aryl alkanone compounds as quenching and/or chelating agents. | 2019-02-14 |
20190046424 | PERSONAL CARE DEODORANT PRODUCT VOID OF ENDOCRINE DISRUPTING CHEMICALS - A personal care deodorant and/or antiperspirant product substantially void of any endocrine disrupting chemicals, and a method of making the same. Embodiments of the deodorant include one or more of the following: a skin conditioning agent, an emollient, a nonaqueous viscosity increasing agent, a surfactant/emulsifying agent, an absorbent, a soothing agent, a deodorant agent, a viscosity-controlling agent, and a scent. | 2019-02-14 |
20190046425 | Oral Care Compositions - An oral care composition comprising (i) basic amino acid in free or salt form, (ii) calcium carbonate, (iii) a fluoride ion source, (iv) a flavoring agent comprising less than 50% menthol, and (v) an anionic surfactant, wherein the anionic surfactant is present in an amount from 1.00 weight % to 1.39 weight % is provided. | 2019-02-14 |
20190046426 | PRO-FRAGRANCE COMPOSITION - A pro-fragrance composition includes a cucurbituril in complex with a fragrance molecule and use of the compositions in counteracting malodour. The cucurbituril is present as a mixture, wherein the mixture includes at least two different cucurbiturils selected from CB[5], CB[6], CB[7] and CB[8]. The complexed fragrance molecule is released when the composition is exposed to a stimulus. Also provides methods for the preparation of pro-fragrance complexes of cucurbiturils and fragrance molecules. | 2019-02-14 |
20190046427 | PEPTIDE HAVING HAIR GROWTH-PROMOTING ACTIVITY AND USE THEREOF - The present invention provides a peptide which shows a hair growth-promoting activity. The peptide of the present invention promotes the growth of follicular cells and increases the expression of a hair growth-related growth factor and hair growth-related factors, thereby showing an excellent effect in hair growth. The peptide of the present invention can be used for preventing and alleviating hair loss, promoting hair growth, and improving hair growth. In addition, the superior activity and stability of the peptide of the present invention allows the peptide to be very favorably applied to quasi drugs and cosmetics. | 2019-02-14 |
20190046428 | COMPOSITION COMPRISING A POLYSACCHARIDE ALKYL ETHER AND INCOMPATIBLE SILICONE OR FLUORINATED OILS AND METHOD EMPLOYING IT - A subject-matter of the present invention is a cosmetic composition comprising: *at least 4% by weight, with respect to the weight of the composition, of at least one polysaccharide alkyl ether comprising at least two different monosaccharide units, each unit comprising at least one hydroxyl group substituted by a C | 2019-02-14 |
20190046429 | DERMAL FILLER COMPOSED OF MACROPOROUS CHITOSAN MICROBEADS AND CROSS-LINKED HYALURONIC ACID - A biocompatible, degradable dermal filler system is composed of unmodified macroporous chitosan microbeads dispersed uniformly in a continuous phase composed of cross-linked hyaluronic acid gel particles and unmodified hyaluronic acid. | 2019-02-14 |
20190046430 | PROTECTIVE LIQUID COSMETIC PRIMER - I disclose a silicone-based liquid cosmetic primer that has utility for protecting skin and makeup. The product is dispensed from a liquid dropper and applied to facial skin before the application of foundation or makeup. It has an extremely high silicone content, 65-99% by weight and preferably 85-95%. The silicone forms a protective layer between the skin and makeup. The silicone barrier formed by this product protects the skin from absorption of irritants and toxins in the cosmetics. Simultaneously, the cosmetic products are protected from oil and sweat for longer-lasting duration. The product also contains small concentrations of Vitamin E, lychee oil, and gold dust. | 2019-02-14 |
20190046431 | HAIR RELAXER COMPOSITIONS AND METHOD - Disclosed is a fiber elasticity conserving hair relaxer composition having an alkalinity of at least pH 12 comprising a fiber elasticity conserving amount of at least one hair fiber elasticity conserving agent selected from the group consisting of poly-organosiloxanes containing, per molecule, at least one siloxyl unit substituted with at least one group having one or more of a sterically hindered piperidinyl functional group. The composition substantially ameliorates the loss of hair fiber elasticity that frequently occurs during the hair relaxing step of a process for relaxing the natural curl of hair under such strongly alkaline conditions. | 2019-02-14 |
20190046432 | TREE BARK EXTRACT AS ANTI-AGING COMPOSITION AND USES THEREOF - The present invention provides a crude extract from the bark of an | 2019-02-14 |
20190046433 | COMBINATION THERAPY FOR COPD - Aerosol formulations comprising glycopyrronium bromide in combination with formoterol are useful for the prevention or treatment of chronic obstructive pulmonary disease. The formulation further comprises a HFA propellant, a co-solvent, and an amount of inorganic acid sufficient to stabilize both the glycopyrronium bromide and the formoterol components. Optionally the formulation may further comprise beclometasone dipropionate. | 2019-02-14 |
20190046434 | NON-INVASIVE OCULAR DRUG DELIVERY INSERT TECHNOLOGY - Non-invasive Ocular Drug Delivery Insert Technology. The invention concerns an ocular insert which is a new biocompatible polymer-based controlled drug delivery system (CDDS) applicable to a variety of drugs and other compounds for the treatment of different ocular pathologies. This ocular insert allows releasing of at least one drug under suitable concentration levels during suitable periods of time. The device may be inserted in the lower or upper fornix conjunctiva, in a non-invasive way, meaning that the patient will be able to place the device himself, without intervention of medical specialized staff. The insert of the invention will release the drug in such a controlled rate that will allow the drug release up to 300 days by either a “Fickian” or a linear profile according to the intend purpose or pathology. The insert can be prepared with different shapes (spherical or spherical dome) and/or architectures (monolithic/layered either with or without a drug core) allowing the incorporation of at least one drug which can be released at different rates. The size, shape and design of the insert is adjusted in order to tune the drug(s) delivery profile(s) and to inhibit the risk of displacement or expulsion. | 2019-02-14 |
20190046435 | MEDICAL DEVICES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME - The present invention recognizes that medical devices, such as but not limited to contact lenses, can be made having a coating made at least in part using printing technologies to provide drug storage and drug release structures. The coating preferably includes at least one drug reservoir layer and a least one barrier layer, and can include structures, such as but not limited to capillary structures, which alone or in combination modulate the release of the drug from the coating. One aspect of the present invention is a medical device that incorporates a drug in at least one coating. A second aspect of the present invention is a method of making a medical device that incorporates a drug in at least one coating. A third aspect of the present invention is a method of using a medical device of the present invention to treat or prevent a disease, disorder or condition. | 2019-02-14 |
20190046436 | NICOTINE FORMULATION AND AEROSOLS - The present disclosure generally relates to nicotine formulations, nebulizer systems comprising same and uses thereof via inhalation. | 2019-02-14 |
20190046437 | COMPLEXES OF ABIRATERONE ACETATE, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present disclosure relates to pharmaceutically acceptable complex formulae comprising complexes of Abiraterone acetate and pharmaceutically acceptable excipients, process for the preparation thereof and pharmaceutical compositions containing them. The complex formulae of the present disclosure have improved physicochemical properties which results in reduced food effect which allows significant dose reduction and the abandoning of the requirement of taking the drug on an empty stomach. | 2019-02-14 |
20190046438 | DELIVERY SYSTEM - In accordance with the present disclosure, there are provided formulations comprising: (a) at least one active agent; (b) an oil, and optionally a thickener therefor; (c) an organic solvent, and a thickener therefor; and (d) an oil and/or solvent soluble skin penetration enhancer; wherein: said formulation comprises <10 wt % water; and said formulation optionally forms a thixotropic thinning gel. Also provided are gels comprising oil and organic solvent, methods for preparing same and methods for the topical delivery of an active agent to a subject in need thereof. | 2019-02-14 |
20190046439 | STABILIZED COMPOSITIONS FOR THE CONTROLLED DELIVERY OF PROBIOTICS AND METHODS OF PRODUCTION THEREOF - A stabilized composition for the controlled delivery of probiotics includes an aqueous solution of crystalloids and colloids comprised of water insoluble polymers with the ability to de-swell upon electrical charge. The composition further includes a plurality of oil droplets and a base solution. The composition further include a destabilizing solution comprising a solvent, nitrogen, a natural acid sufficient to produce a pH of about 3.0 to about 4.5, and a sufficient amount of a salt to contribute to an osmolality between about 190 mOsm/L and about 900 mOsm/L. The composition further includes a plurality of microencapsulated probiotic beads, wherein the plurality of microencapsulated probiotic beads comprises between about 0.01% to about 20% of the composition by weight. | 2019-02-14 |
20190046440 | METHODS AND SYSTEMS FOR FORMING STABLE DROPLETS - The present disclosure provides methods and systems for forming stable droplets as part of an emulsion. The emulsion may be, for example, formed by bringing an aqueous phase in contact with an oil phase at a droplet generation junction of a droplet generator. Droplets of the present disclosure may be used for holding compositions for various uses. | 2019-02-14 |
20190046441 | RINSE-OFF SELF-FOAMING CLEANSING COMPOSITION CONTAINING IVERMECTIN - A self-foaming composition including ivermectin is described for a no-rinse topical application and for application to the skin. The composition can include at least one intermediate composition B including a gas-generating agent; at least one intermediate composition A including an agent for activating the gas-generating agent; and ivermectin being present in at least one of the intermediate compositions A and B. Also described, is a kit or a single container including a plurality of compartments including such a composition. | 2019-02-14 |
20190046442 | IMPROVEMENT OF EXPRESSION AND FOLDING IN THE MANUFACTURING PROCESS OF CD-RAP BY USING A CD-RAP PRECURSOR PROTEIN - The present invention relates to a CD-RAP precursor protein comprising a pre-sequence and CD-RAP, and its use in manufacturing of native CD-RAP. The present invention further relates to a composition comprising CD-RAP and at least one positively charged amino acid and a buffer, pharmaceuticals comprising said composition, their use in methods of treating and/or preventing cartilage disease or injury in patients suffering from aggrecan degradation, and/or increased influx of water into the cartilage, and/or decreased CD-RAP expression, as well as methods of producing said composition and methods of storing CD-RAP in said composition. The present invention further relates to a composition comprising liposomes comprising encapsulated CD-RAP or a variant thereof, its use in methods of treating joint disease or injury, and methods of producing such liposomal composition as well as storing CD-RAP therein. | 2019-02-14 |
20190046443 | LIPOSOMES FOR MODULATING WISKOTT-ALDRICH SYNDROME PROTEIN - Embodiments of the invention relate to liposomes comprising: a lipid bilayer having an internal cavity; a therapeutic agent within the internal cavity configured to modify expression or degradation of WASp in a cell; and a targeting moiety external to the lipid bilayer configured to target an extracellular domain of a cell. Embodiments of the invention relate to methods of treatment of disease comprising administering the liposomes. Novel pharmaceutical compositions are also disclosed. | 2019-02-14 |
20190046444 | A STERICALLY STABILIZED CARRIER FOR SUBCUTANEOUS, SUBLINGUAL, AND ORAL THERAPEUTICS, COMPOSITIONS AND METHODS FOR TREATING A MAMMAL - Disclosed herein are pharmaceutical compositions and methods for oral, sublingual or subcutaneous administration comprising a sterically stabilized liposome carrier comprising: i) poly (ethylene glycol) distearoylphosphatidylethanolamine (PEG-DSPE); and ii) at least one of phosphatidylglycerol and phosphatidylcholine. Compositions and methods for treatment of food allergy and eosinophilic esophagitis are also described. | 2019-02-14 |
20190046445 | CHEMOTACTIC, DRUG-CONTAINING POLYMERSOMES - The present invention relates to polymersomes that contain an encapsulated drug and that exhibit chemotaxis in response to a chemical stimulus. The chemotactic polymersomes can be targeted in vivo to a location of therapeutic interest with high specificity and selectivity. The present invention also provides related pharmaceutical compositions and therapeutic methods. | 2019-02-14 |
20190046446 | APO-E MODIFIED LIPID NANOPARTICLES FOR DRUG DELIVERY TO TARGETED TISSUES AND THERAPEUTIC METHODS - Lipid nanoparticles and methods of making and using the same, including pharmaceutical compositions and kits, and the targeted delivery of drugs in various treatment methods. The nanoparticle formulation includes phospholipids, triglycerides, cholesterol, cholesteryl ester, apolipoprotein E3 (ApoE3), and a lipophilic therapeutic agent. | 2019-02-14 |
20190046447 | TEMPERATURE-SENSITIVE COMPOSITE AND METHOD FOR PREPARING SAME - The present invention relates to a temperature-sensitive composite and a method for preparing the same. The temperature-sensitive composite according to the present invention is maintained in a liquid state at room temperature and solidified at the time of delivery in the body, and shows remarkably excellent improvement in mechanical properties compared with an existing temperature-sensitive polymer composite, and as a result, the temperature-sensitive composite can promote the stability of a drug delivery system in the body and the sustainment of drug release. | 2019-02-14 |
20190046448 | MICROPARTICLE FORMULATIONS OF ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING CANCER - The invention provides compositions comprising microparticles wherein the microparticles comprise at least one adenosine 2 | 2019-02-14 |
20190046449 | A UNIQUE HIGH-SHEAR GRANULATION PROCESS FOR IMPROVED BIOAVAILABILITY OF RIVAROXABAN - Method for preparing granules of rivaroxaban together with pharmaceutically acceptable excipients using high-shear mixing. The granules produced by the methods disclosed herein may be incorporated into dosage forms for oral administration having enhanced oral bioavailability of rivaroxaban. | 2019-02-14 |
20190046450 | LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE - The present disclosure relates to solutions and methods of preparing lyophilized formulations of factor Xa (fXa) antidotes. A suitable aqueous formulation suitable for lyophilization can include a fXa antidote, a solubilizing agent, and a stabilizer, wherein the formulation does not collapse during lyophilization. | 2019-02-14 |
20190046451 | CHOLESTYRAMINE PELLETS, ORAL CHOLESTYRAMINE FORMULATIONS AND USE THEREOF - The invention relates to small pellets comprising cholestyramine. The pellets have a high cholestyramine content and are stable enough to be coated with one or more coating layers. The invention also relates to a multiparticulate drug delivery system comprising such pellets. The invention further relates to an oral formulation for targeted delivery of cholestyramine to the colon, comprising a plurality of cholestyramine pellets that are coated with a colon release coating. The invention also relates to the use of this formulation in the treatment of bile acid malabsorption and bile acid diarrhoea. | 2019-02-14 |
20190046452 | PREPARATION CONTAINING 6,7-UNSATURATED-7-CARBAMOYL MORPHINAN DERIVATIVES - The solid preparation which improved the dissolution profile and the stability of the 6,7-unsaturation-7-carbamoyl morphinan derivative is provided. When 6,7-unsaturation-7-carbamoyl morphinan derivative, croscarmellose sodium and ferric oxide were contained, not titanium oxide in the solid preparations and the coating solid preparations, a dissolution rate after 15 minutes of the dissolution test is more than 85%, and stability, particularly, light stability can be improve. | 2019-02-14 |
20190046453 | CONTROLLED RELEASE AND TASTE MASKING ORAL PHARMACEUTICAL COMPOSITION - Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract. | 2019-02-14 |
20190046454 | HARD CAPSULES - Publicly available pullulan hard capsule shells present certain drawbacks, notably a non fully satisfactory shell mechanical strength (i.e. shell brittleness) at shell low LOD. Improving this property is a particularly desirable goal for pullulan hard capsule shells. The present invention solves this and other objects by providing new hard pullulan capsule shells and capsules comprising (I) moisture, (II) a mono-, di-, and oligosaccharides free pullulan and (III) a setting system. Also provided are an aqueous composition and a dip-molding manufacturing method for the manufacture of such shells and capsules. | 2019-02-14 |
20190046455 | STIMULI-RESPONSIVE INTERPOLYMER COMPLEX COATED HOLLOW SILICA VESICLES - A porous hollow silica particle with an interpolymer complex immobilized thereon is provided. The interpolymer complex comprises a first polymer immobilized to a surface of the silica particle, and a second polymer complexed with the first polymer. Pharmaceutical compositions comprising the silica particle, and methods of forming the silica particle are also provided. | 2019-02-14 |
20190046456 | PHARMACEUTICAL BEAD FORMULATIONS COMPRISING DIMETHYL FUMARATE - The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention comprises a first pharmaceutical bead composition and a second pharmaceutical bead composition, wherein the first pharmaceutical bead composition is an enterically coated immediate-release composition and the second pharmaceutical bead composition is an enterically coated controlled-release composition, wherein the first pharmaceutical bead composition and the second pharmaceutical bead composition both comprise dimethyl fumarate Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included. | 2019-02-14 |
20190046457 | COMPOSITIONS COMPRISING PROTON PUMP INHIBITORS - A composition suitable for forming a viscous suspension upon admixing with an aqueous medium, methods for its production and use thereof are provided. The composition includes a plurality of units, each unit having a core containing a proton | 2019-02-14 |
20190046458 | SPRINKLE FORMULATIONS OF ACAMPROSATE - The present invention provides an orally-administrable, pharmaceutical formulation comprising: a plurality of pellets, wherein: the pellets comprise a core, a sustained release coating, and an enteric coating; and the core comprises an active ingredient and a diluent. | 2019-02-14 |
20190046459 | Preparation Containing Esomeprazole - The present invention relates to a preparation containing esomeprazole as an active ingredient. The present invention is characterized in that a controlled-release system is introduced such that the efficacy of esomeprazole, which is an active ingredient, can be continuously exhibited. | 2019-02-14 |
20190046460 | Methods and Compositions Particularly for Treatment of Attention Deficit Disorder - There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described. | 2019-02-14 |
20190046461 | VIRAL VECTOR NANOCAPSULE FOR TARGETING GENE THERAPY AND ITS PREPARATION - The invention provides novel methods, materials and systems that can be used to generate viral vectors having altered tissue and cell targeting abilities. In illustrative embodiments of the invention, the specificity of lentiviral vectors was modulated by a thin polymer shell that synthesized and coupled to the viral envelope in situ. The polymer shell can confers such vectors with new targeting ability via agents such as cyclic RGD (cRGD) peptides that are coupled to the polymer shell. These polymer encapsulated viral vectors exhibit a number of highly desirable characteristics including a higher thermal stability, resistance to serum inactivation in vivo, and an ability to infect dividing and non-dividing cells with high efficiencies. | 2019-02-14 |
20190046462 | Targeted Delivery of Hydrophilic Drugs - A method of designing a pharmaceutical composition for providing the liver of a person or animal, as a therapeutic target, with a predetermined concentration of a sulfate or sulfonate of a pharmacologically active agent, during a predetermined period, includes determining the correlation between the solubility of a sulfate and/or sulfonate of a pharmacologically active agent of the formula D | 2019-02-14 |
20190046463 | ULTRAVIOLET-HARDENING HYDROGEL RESIN AND HYDROGEL FOR TRANSDERMAL ADMINISTRATION, AND CATAPLASM AGENT CONTAINING SAME - The present invention relates to a UV-curable hydrogel resin for transdermal administration, a hydrogel prepared using the UV-curable hydrogel resin, and a cataplasm prepared using the UV-curable hydrogel resin. More particularly, the present invention relates to a hydrogel resin with an optimal composition and composition ratio which allows increase in a water content of a hydrogel applied as a drug layer of a cataplasm, skin irritation mitigation, and crosslinking degree adjustment for adhesion control and is capable of controlling drug releasing property and transdermal absorbability, a hydrogel prepared by UV-hardening the hydrogel resin, and a cataplasm including the hydrogel. | 2019-02-14 |
20190046464 | ADHESIVE PATCH - An adhesive patch comprising: a support; at least a pressure-sensitive adhesive layer provided on the support; and a release liner attached on the pressure-sensitive adhesive layer so as to cover the surface of the pressure-sensitive adhesive layer, in which the support is a 3D patterned sheet characterized in that a plurality of protruded lines and recessed lines parallelly and linearly extending are formed inside and outside lines in a plurality of figures partitioned by the lines, walls of the protruded lines and recessed lines in some of the figures are formed to be inclined by different inclination angles with respect to a base part, and the protruded lines have different heights from the base part, serving as physical parameters of the protruded lines and recessed lines, toward a predetermined direction in the sheet. | 2019-02-14 |
20190046466 | COMPOSITION AND METHOD FOR INHIBITING PLATELET AGGREGATION - Pharmaceutical compositions containing a stilbene such as resveratrol, a flavonol such as quercetin, and a μ-opioid receptor antagonist such as naltrexone inhibit aggregation of superactivated platelets, block activation of the coagulation cascade, and are useful for treating microvascular diseases including neurodegenerative diseases such as Alzheimer's disease and dementia, for treating primary open-angle glaucoma, for reducing scar formation, and like afflictions that involve the coagulation cascade. | 2019-02-14 |
20190046467 | COMPOSITIONS AND METHODS FOR INHIBITING BIOFILM-FORMING BACTERIA - The present disclosure provides, among other things, compositions and methods useful for inhibiting biofilm-forming bacteria. For example, the compositions and methods described herein can be used to inhibit the proliferation, viability, and/or biofilm-forming activity, of biofilm-forming bacteria. | 2019-02-14 |
20190046468 | EXTENDED RELEASE LIQUID COMPOSITIONS OF GUAIFENESIN - The present invention relates to extended release liquid compositions of guaifenesin. The extended release liquid compositions are in the form of suspensions which are ready-to-use or suspensions which are reconstituted from powder. It also relates to processes for the preparation of said extended release liquid compositions. | 2019-02-14 |
20190046469 | COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS OR SKIN DISEASE OR DAMAGE - Methods for the treatment of mood disorders and/or skin disease or damage (eczema, atopic dermatitis, or wrinkles, for example) can comprise administering an extracted prenylflavonoid to a subject experience the mood disorder or the skin disease or damage. | 2019-02-14 |
20190046470 | NEW USE OF TUMOR GENE METHYLATION REGULATOR AND ANTI-TUMOR DRUGS - Disclosed is the use of a tumor gene methylation regulator in preparing anti-tumor drugs. Furthermore, the tumor gene methylation regulator can be used as a sensitizer to be combined with a tumor therapeutic drug for preparing anti-tumor drugs. | 2019-02-14 |
20190046471 | Methods and Compositions for the Treatment of Steatosis-Associated Disorders - The present disclosure is directed to methods of treating a steatosis-associated disorder by administering a therapeutic agent selected from a lysosomal enzyme, an autophagy-inducing agent, or a combination thereof. Steatosis-associated disorders discussed herein include GSD la, GSD lb, GSD Ic, NAFLD, and NASH. Other embodiments are directed to methods of reversing steatosis, modulating autophagy, inducing autophagy, and reversing glycogen storage. | 2019-02-14 |
20190046472 | IGMESINE FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES - The present invention relates to methods for treating neurodegenerative diseases and disorders with igmesine. | 2019-02-14 |
20190046473 | NOREPINEPHRINE COMPOSITIONS AND METHODS THEREFOR - The inventive subject matter is directed to compositions and methods for ready-to-inject norepinephrine compositions with improved stability. Most preferably, compositions presented herein are substantially antioxidant free and exhibit less than 10% isomerization of R-norepinephrine and exhibit less than 5% degradation of total norepinephrine. | 2019-02-14 |
20190046474 | NOREPINEPHRINE COMPOSITIONS AND METHODS THEREFOR - The inventive subject matter is directed to compositions and methods for ready-to-inject norepinephrine compositions with improved stability. Most preferably, compositions presented herein are substantially antioxidant free and exhibit less than 10% isomerization of R-norepinephrine and exhibit less than 5% degradation of total norepinephrine. | 2019-02-14 |
20190046475 | ORAL VETERINARY COMPOSITION WITH GABAPENTIN - The present invention relates to a solid veterinary pharmaceutical composition, of oral administration comprising: a) a drug selected from gabapentin and/or fluoxetine or a pharmaceutically acceptable salt thereof, preferably gabapentin or an acceptable salt thereof in a concentration from 10 to 1000 mg; b) from 10% to 80% of the composition total weight of at least one silicon salt selected preferably from silicon dioxide, colloidal silicon dioxide, calcium silicate, magnesium silicate or combinations thereof; c) from 1% to 20% of the composition total weight of at least one polyoxyethylenated sorbitan ester, preferably selected from sorbitan monolaurate, sorbitan monooleate and sorbitan trioleate, or combinations thereof; and d) one or more pharmaceutically acceptable excipients; such that it is optimally prepared as a veterinary pharmaceutical product that exhibits safety and efficacy in mammalian animals, preferably in companion animals. | 2019-02-14 |
20190046476 | S-ENANTIOMERICALLY ENRICHED COMPOSITIONS OF BETA BLOCKERS FOR TREATING MUSCLE WEAKNESS - The use of S-enantiomerically enriched compositions of beta blockers for treating muscle weakness. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof. | 2019-02-14 |
20190046477 | COMPOSITION FOR TREATING DIABETES, CONTAINING EXTRACT OF YUKMIJIHWANGTANG - Provided is a composition for treating diabetes, including a hypoglycemic agent and a Yukmijihwang-tang extract. More particularly, the hypoglycemic agent is administered into an individual, and the Yukmijihwang-tang extract is administered into the individual, thereby considerably increasing a hypoglycemic effect of the hypoglycemic agent, and preventing and reducing various diabetic complications such as diabetes and diabetic liver damage, renal damage, hyperlipidemia immunosuppression and ocular damage. | 2019-02-14 |
20190046478 | BIOLOGICAL MARKER FOR IDENTIFYING CANCER PATIENTS FOR TREATMENT WITH A BIGUANIDE - The disclosure features a method of determining whether a patient diagnosed as having cancer is likely to respond to treatment with an effective amount of a biguanide. This method includes (a) determining an expression level of miR-17˜92 in a sample obtained from the patient; and (b) comparing the expression level to a reference expression level of miR-17˜92, where an increased expression level of miR-17˜92 in the sample as compared to a reference expression level identifies the patient as one who is likely to respond to treatment including administration of the effective amount of the biguanide. Also featured are methods of treating patients having a cancer that is likely to respond to treatment with an effective amount of a biguanide. | 2019-02-14 |
20190046479 | METHODS, COMPOSITIONS, AND DEVICES FOR DRUG / LIVE CELL MICROARRAYS - Methods and compositions are for preparing microimplant arrays for sustained drug delivery or live cell based therapy. The “array in array” (AIA) device enables formation of microimplant arrays without having tissue piercing elements to the microimplant. The methods and compositions are for solid state delivery of drugs, especially biologics drugs without forming a drug solution prior to injection. New methods and compositions are for preparing in situ arrays for sustained drug delivery or live cell based therapy. Tissue surface is first treated with laser drilling, microneedle array, mechanical drilling or other methods to create artificial micro-porosity of various sizes, shapes and patterns. The artificial pores created are then infused with sustained drug delivery compositions or live cell suspensions. The compositions are converted into solid or semisolid state by physical or chemical reaction/s to entrap drug or live cells. The entrapped drug or live cells provide local or systemic therapeutic benefit. | 2019-02-14 |
20190046480 | METHODS OF TREATING DEVELOPMENTAL DISORDERS WITH BIGUANIDES - Methods of treating developmental disorders such as Angelman syndrome, Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome (FXTAS), Autistic Spectrum Disorder, Autism, Asperger's syndrome, pervasive developmental disorder, Childhood Disintegrative Disorder, Rett syndrome, Landau-Kleffner Syndrome, Prader-Willi Syndrome, Tardive Dyskinesia, a seizure disorder and/or Williams Syndrome with a biguanide such as metformin, buformin, phenformin or a pharmaceutically acceptable salt thereof are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of the developmental disorder. | 2019-02-14 |
20190046481 | TRANSDERMAL FORMULATIONS FOR DELIVERY OF PROPIONIC AND ACETIC ACID NSAIDS, AND THEIR USE IN THE TREATMENT OF NSAID-RESPONSIVE DISEASES AND CONDITIONS - The present application is directed to transdermal formulations for the delivery of propionic and acetic acid NSAIDs to a subject for the treatment of NSAID-responsive diseases. In particular, the transdermal formulation is an emulsion comprising an oil phase, an aqueous phase and an external phase. | 2019-02-14 |
20190046482 | COMPOSITIONS AND METHODS FOR IMPROVING MITOCHONDRIAL FUNCTION - The disclosure provides compositions comprising tricarboxylic acid cycle intermediates and at least one anti-oxidant. In one embodiment, the composition comprises pyruvic acid, citric acid and malic acid in combination with the anti-oxidant ascorbic acid. The disclosure also provides methods and uses of the compositions for improving mitochondrial function and physical recovery post-exertion. | 2019-02-14 |
20190046483 | Small Molecule Agents, Compositions, and Formulations, for Internal Use, Displaying Inhibitory Activity Against Gram-Positive and/or Gram-Negative Organisms - Active components comprising lauric acid, or a lauric acid derivative, are utilized independently, or in combination, to provide new and useful compositions for bacteriostatic action against susceptible pathogens. The lauric acid derivative includes one or more of 12-aminododecanoic acid, 12-amino-1-dodecanoic acid methyl ester, sucrose monolaurate, 12-(7-nitrobenzofurazan-4-ylamino) dodecanoic acid, 4-nitrophenyl dodecanoate, 1-lauroyl-rac-glycerol, 3-oxo-N-(2-oxocyclohexyl) dodecanamide, butyl laurate, benzyl laurate, isoamyl laurate, monolaurin, isopropyl laurate, pentyl laurate, and hexyl laurate. A preparation includes combining the active component with lecithin, and after an initial processing phase, coating with chitosan or a carrier. Final compositions may be or may contain particles, such as nanoparticles. Final compositions, or formulations containing said final compositions, may be utilized internally, causing one or more membrane changes (e.g., a membrane of an internal target pathogen, which may or may not be an antibiotic-resistant pathogen). At least some compositions inhibit growth of one or more Gram-positive bacterial species and one or more Gram-negative bacterial species. | 2019-02-14 |
20190046484 | METHODS FOR TREATING NEUROBLASTOMA - The present invention provides methods and kits a) for preventing and/or treating neuroblastoma (e.g., high-risk neuroblastoma) that is linked, in part, to high levels of ODC activity and increased cellular polyamine content, b) for predicting cancer patient survival, especially cancer patients whose cancer is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and c) for selecting treatment options for such patients based on the allelic nucleotide sequence or SNP at positions +263 and/or +316 of the ODC1 gene. The invention also provides, cancer treatment methods comprising the determination of the ODC1 genotype at the +263 and/or +316 positions, as a means to guide treatment selection, which includes, in some aspects the administration of pharmaceutically effective amounts of α-difluoromethylomithine (DFMO), either as a monotherapy or in combination with one or more other drugs. In addition, the present invention provides methods for preventing and/or treating patients that have been determined to have cancer stem cells, such as patients in cancer remission that are at risk for relapse. | 2019-02-14 |
20190046485 | COMPOSITIONS FOR TREATMENT OF PAIN IN PATIENTS WHO UNDERWENT ELECTIVE ANTHROPLASTY - Amino acids compositions for use in the treatment of pain in patients who underwent elective arthroplasty. | 2019-02-14 |
20190046486 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURONAL INJURY - This disclosure provides compositions and methods for treating or preventing neuronal injury in a subject, e.g., a subject at risk of or having traumatic brain injury or stroke. | 2019-02-14 |
20190046487 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES AND DISORDERS ASSOCIATED WITH ONE OR BOTH OF HYPERAMMONEMIA OR MUSCLE WASTING - This disclosure provides compositions and methods for treating or preventing liver diseases and disorders with hyperammonemia or muscle wasting in a subject. | 2019-02-14 |
20190046488 | ANTIMICROBIAL COMPOSITIONS AND USES THEREOF - In some aspects, provided herein are antimicrobial compositions comprising partially esterified polygalacturonic acid and certain fatty acids (e.g., caprylic acid). In some embodiments, the antimicrobial composition may be administered (e.g., topically or orally) to a subject, such as a human patient to treat an infection (e.g., an infection comprising a biofilm). In some aspects, improved catheters are provided. | 2019-02-14 |
20190046489 | LIPID SCAVENGING IN RAS CANCERS - Methods and compositions for treating Ras-related cancers are provided that involve targeting lipid scavenging. Methods and compositions for identifying and/or characterizing more or less responsive cancers are also provided. | 2019-02-14 |
20190046490 | METHODS OF TREATING LACTOSE INTOLERANCE - Disclosed herein in part are methods for treating lactose intolerance, including administering fatty acid compounds that modulate PPARγ receptors. | 2019-02-14 |
20190046491 | OXIDATIVE RETINAL DISEASES - Some aspects of the invention provide for a method of treating Wet and/or Dry Age-related Macular Degeneration, Retinitis Pigmentosa, Diabetic Retinopathy, cataracts, and/or Stargardt Disease using polyunsaturated fatty acids which are modified in certain positions to attenuate oxidative damage by Reactive Oxygen Species (ROS) and/or suppress the rate of formation of reactive products and toxic compounds. | 2019-02-14 |
20190046492 | TREATMENT AND PREVENTION OF BONE LOSS USING RESOLVINS - The invention provides new methods for inducing or promoting bone growth and/or for reducing or preventing bone deterioration in a mammal subject. The inventive methods generally comprise administering to the subject an effective amount of a resolving. In particular, the inventive methods may be useful for treating or preventing conditions associated with bone degradation, deterioration or degeneration such as periodontal disease, osteoarthritis, and metastatic bone disease and osteolytic bone disease. Pharmaceutical compositions and kits comprising at least one resolving are also provided that can be used to performed the inventive methods. | 2019-02-14 |
20190046493 | LIQUID EXTERNAL PREPARATION - The present invention provides a liquid topical preparation having low “stickiness” even when it contains a high concentration of an anticholinergic drug. The liquid topical preparation comprises water, an anticholinergic drug and dicarboxylic acid ester, and the content of the anticholinergic drug ranges from 10 mass % to 20 mass % based on the total mass of the liquid topical preparation. | 2019-02-14 |
20190046494 | Lactylates for the prevention and treatment of infections caused by gram-positive bacteria in animals - The present invention pertains to the use for preventing or treating intestinal infections caused by gram-positive bacteria in animals of an antibacterial compound selected from lactylate in accordance with formula 1, | 2019-02-14 |
20190046495 | Reducing the Risk of Pathological Effects of Traumatic Brain Injury - The present disclosure provides methods and compositions for reducing the risk of pathological effects of traumatic brain injury. | 2019-02-14 |
20190046496 | USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR OF MORTALITY - Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto. | 2019-02-14 |
20190046497 | METHODS OF MODULATING PROTEIN EXOCYTOSIS AND USES OF SAME IN THERAPY - A method of modulating protein exocytosis is provided. The method comprising contacting a cell with an agent that modulates the ubiquitin pathway in the Golgi, thereby modulating protein secretion. | 2019-02-14 |
20190046498 | METHOD FOR TREATING MELANOMA - Disclosed is a method of inhibiting growth of a melanoma cancer cell. The method includes contacting the melanoma cancer cell with an effective amount of a composition and the composition contains polymethoxyflavone. The polymethoxyflavone can be applied in an amount of 0.1 μmol/L-1000 μmol/L. A method of treating a subject having melanoma with the above discussed composition is also included. | 2019-02-14 |